Fox Run Management L.L.C. Grows Stake in Royalty Pharma plc (NASDAQ:RPRX)

Fox Run Management L.L.C. increased its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 41.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,062 shares of the biopharmaceutical company's stock after acquiring an additional 16,084 shares during the period. Fox Run Management L.L.C.'s holdings in Royalty Pharma were worth $1,405,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of RPRX. Franklin Resources Inc. boosted its position in Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after purchasing an additional 70,130 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Royalty Pharma by 4.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after buying an additional 130,025 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in shares of Royalty Pharma in the 4th quarter worth about $2,355,000. Jupiter Asset Management Ltd. bought a new position in Royalty Pharma during the fourth quarter valued at about $4,950,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Royalty Pharma by 303.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock worth $13,926,000 after buying an additional 406,123 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Royalty Pharma Stock Performance

RPRX traded down $0.12 during trading hours on Tuesday, hitting $33.63. The stock had a trading volume of 1,467,174 shares, compared to its average volume of 2,847,233. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company's fifty day simple moving average is $32.33 and its 200 day simple moving average is $28.75. The stock has a market cap of $19.39 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.62%. Royalty Pharma's dividend payout ratio is currently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.